Home FDA panel rejects Merck claim Zetia/Vytorin cut heart risk
 

Keywords :   


FDA panel rejects Merck claim Zetia/Vytorin cut heart risk

2015-12-15 10:29:34| Biotech - Topix.net

Dec 14 Merck & Co should not be allowed to claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease, an advisory committee to the U.S. Food and Drug Administration concluded on Monday.

Tags: heart risk cut panel

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.07Importance of good feeding practices for pasture management
01.07Hurricane Beryl Update Statement
01.07Summary for Hurricane Beryl (AT2/AL022024)
01.07Beckers Group Announces Leadership Changes
01.07Pixellot powers Top Hockey League's new OTT viewing platform
01.0744p selects Harmonic for UHD playout, media processing and distribution
01.07Dailymotion integrated into NetRange's in-car video solution
01.07X-Rite wins PRINTING United Alliance 2024 Pinnacle Product Award
More »